home / stock / avir / avir quote
Last: | $3.28 |
---|---|
Change Percent: | 0.31% |
Open: | $3.22 |
Close: | $3.28 |
High: | $3.35 |
Low: | $3.21 |
Volume: | 165,365 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.28 | $3.22 | $3.28 | $3.35 | $3.21 | 165,365 | 07-03-2024 |
$3.23 | $3.37 | $3.23 | $3.37 | $3.22 | 227,171 | 07-02-2024 |
$3.37 | $3.29 | $3.37 | $3.4 | $3.205 | 253,987 | 07-01-2024 |
$3.31 | $3.41 | $3.31 | $3.41 | $3.245 | 693,550 | 06-28-2024 |
$3.38 | $3.37 | $3.38 | $3.42 | $3.35 | 165,910 | 06-27-2024 |
$3.37 | $3.41 | $3.37 | $3.49 | $3.34 | 264,525 | 06-26-2024 |
$3.43 | $3.46 | $3.43 | $3.59 | $3.41 | 210,571 | 06-25-2024 |
$3.49 | $3.44 | $3.49 | $3.555 | $3.41 | 200,414 | 06-24-2024 |
$3.44 | $3.43 | $3.44 | $3.61 | $3.36 | 641,153 | 06-21-2024 |
$3.42 | $3.46 | $3.42 | $3.58 | $3.4 | 231,889 | 06-20-2024 |
$3.49 | $3.52 | $3.49 | $3.65 | $3.49 | 227,132 | 06-19-2024 |
$3.49 | $3.52 | $3.49 | $3.65 | $3.49 | 227,132 | 06-18-2024 |
$3.53 | $3.6 | $3.53 | $3.65 | $3.515 | 387,103 | 06-17-2024 |
$3.61 | $3.7 | $3.61 | $3.74 | $3.58 | 264,277 | 06-14-2024 |
$3.7 | $3.78 | $3.7 | $3.85 | $3.69 | 233,693 | 06-13-2024 |
$3.78 | $3.92 | $3.78 | $3.97 | $3.78 | 283,351 | 06-12-2024 |
$3.92 | $3.76 | $3.92 | $3.92 | $3.69 | 223,058 | 06-11-2024 |
$3.79 | $3.68 | $3.79 | $3.94 | $3.645 | 754,470 | 06-10-2024 |
$3.7 | $3.75 | $3.7 | $3.85 | $3.695 | 162,231 | 06-07-2024 |
$3.8 | $3.93 | $3.8 | $3.95 | $3.799 | 221,140 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...